SAGE Therapeutics Inc (SAGE) was Upgraded by Chardan Capital Markets to ” Neutral” and the brokerage firm has set the Price Target at $60. Earlier the firm had a rating of “Sell ” on the company shares. Chardan Capital Markets advised their Clients and Investors in a research report released on Feb 14, 2017.
Several company insiders have filed Insider transactions , on Jan 13, 2017, Kimi Iguchi (CFO, Secretary and Treasurer) sold 10,000 shares at $53.92 per share price. According to the SEC, on Jul 14, 2016, Albert Robichaud (Chief Scientific Officer) sold 22,000 shares at $40.00 per share price. On Apr 21, 2016, Stephen Kanes (Chief Medical Officer) sold 21,000 shares at $38.00 per share price, according to the Form-4 filing with the securities and exchange commission.
SAGE Therapeutics Inc closed down -0.12 points or -0.25% at $47.42 with 2,25,070 shares getting traded on Friday. Post opening the session at $47.71, the shares hit an intraday low of $47.06 and an intraday high of $48.36 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.